Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,333,825 papers from all fields of science
Search
Sign In
Create Free Account
CCNE2 protein, human
Known as:
Cyclin E2
, Cyclin-E2
, CCNE2
Expand
G1/S-specific cyclin-E2 (404 aa, ~47 kDa) is encoded by the human CCNE2 gene. This protein plays a role in cell cycle checkpoint regulation between…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
CCNE2 gene
Cell Cycle Control
Cell Nucleus
Genes, Regulator
Expand
Broader (1)
Cyclins
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Does retinoic acid reverse cell cycle dysregulation in Alzheimer's disease lymphocytes?
Aparna Ashok
,
Safoora Naaz
,
+9 authors
B. Viswanath
Asian Journal of Psychiatry
2019
Corpus ID: 52076879
2017
2017
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer
Wei Song
,
L. Tang
,
+5 authors
X. Guan
Scientific Reports
2017
Corpus ID: 16327500
Emerging evidence has shown that adding poly(ADP-ribose) polymerase (PARP) inhibitors to chemotherapy regimens is superior to the…
Expand
2017
2017
The role of miR-26 a and miR-30 b in HER 2 + breast cancer trastuzumab resistance and regulation of the CCNE 2 gene
Eduardo
,
A. Adam-Artigues
,
+8 authors
P. Eroles
2017
Corpus ID: 54199420
A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been…
Expand
2017
2017
Microarray expression analysis of MYCN-amplified neuroblastoma cells after inhibition of CDK2.
H. Song
,
F. Wu
,
+4 authors
C. Lin
Neoplasma (Bratislava)
2017
Corpus ID: 30588335
The study aimed to explore the underlying molecular mechanisms of CDK2 inhibition in neuroblastoma by bioinformatics analysis…
Expand
2016
2016
Detection of gene copy number alterations in DCIS and invasive breast cancer by QM-FISH.
Aifeng Pan
,
Yawei Zhou
,
+4 authors
Li Li
American journal of translational research
2016
Corpus ID: 22554295
The exact roles of copy number alteration (CNA) in initiation, progression and immunotherapy of breast cancer and the genomic…
Expand
2015
2015
Role of Non-coding RNAs in chemotherapeutic treatments
I. Vannini
2015
Corpus ID: 73662333
The transcribed ultraconserved regions (T-UCRs) are a group of long non-coding RNAs involved in human carcinogenesis. The factors…
Expand
2014
2014
[Evaluation of c-myc and CCNE2 amplification in breast cancer with quantitative multi-gene fluorescence in-situ hybridization].
Zhishuang Li
,
Qingyong Meng
,
Qiong Yu
,
Zhiqiang Zhou
,
Li Li
Zhonghua bing li xue za zhi = Chinese journal of…
2014
Corpus ID: 19128496
OBJECTIVE To investigate c-myc and CCNE2 gene amplifications and their relationship in breast cancer. METHODS Sixty-six…
Expand
2011
2011
Abstract 3952: MicroRNA miR-34b/c is significantly down-regulated by aberrant promoter methylation and forced expression of miR-34b/c enhances the radiosensitivity in malignant pleural mesothelioma…
Y. Maki
,
S. Toyooka
,
+9 authors
S. Miyoshi
2011
Corpus ID: 75311994
MicroRNA miR-34b/c, one of the direct transcriptional targets of p53, plays an important role in tumor-suppressor network. It is…
Expand
2006
2006
Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients
C. Desmedt
,
F. Ouriaghli
,
+10 authors
C. Sotiriou
International Journal of Cancer
2006
Corpus ID: 20549978
Uncontrolled cell proliferation is one of the hallmarks of cancer and the transition from the G1 to S phase is the most commonly…
Expand
2005
2005
High avidity cyclin E1-derived peptide-specific CTL kill lymphoid leukemia cells and cross-recognize a homologous cyclin E2-derived peptide
Y. Kondo
,
E. Wieder
,
Sijie Lu
,
J. Molldrem
2005
Corpus ID: 70650391
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE